PTPN4

Across TCGA pan-cancer cohorts, PTPN4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTPN4 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTPN4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PTPN4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PTPN4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.969	0.621	<.001	73	view →
LUAD	DFS	Tertile	All	0.838	0.629	.007	11	view →
LSCC	OS	Quartile	All	0.711	0.961	.016	11	view →
UCEC	OS	Tertile	III,IV	0.346	1.000	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PTPN4–PDAC (OS)

Open the PDAC breakdown →